KURA vs. XNCR, IRWD, AIMT, RARX, ZYME, KRYS, OGN, APLS, RNA, and CRNX
Should you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Xencor (XNCR), Ironwood Pharmaceuticals (IRWD), Aimmune Therapeutics (AIMT), Ra Pharmaceuticals (RARX), Zymeworks (ZYME), Krystal Biotech (KRYS), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Avidity Biosciences (RNA), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "medical" sector.
Kura Oncology (NASDAQ:KURA) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking.
Xencor has higher revenue and earnings than Kura Oncology. Xencor is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Kura Oncology has a net margin of 0.00% compared to Xencor's net margin of -82.23%. Xencor's return on equity of -20.29% beat Kura Oncology's return on equity.
In the previous week, Xencor had 1 more articles in the media than Kura Oncology. MarketBeat recorded 4 mentions for Xencor and 3 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 1.24 beat Xencor's score of 1.11 indicating that Kura Oncology is being referred to more favorably in the media.
Kura Oncology has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.
Xencor received 91 more outperform votes than Kura Oncology when rated by MarketBeat users. Likewise, 73.05% of users gave Xencor an outperform vote while only 69.11% of users gave Kura Oncology an outperform vote.
Kura Oncology presently has a consensus price target of $31.33, indicating a potential upside of 48.57%. Xencor has a consensus price target of $35.38, indicating a potential upside of 63.39%. Given Xencor's higher probable upside, analysts clearly believe Xencor is more favorable than Kura Oncology.
Summary
Xencor beats Kura Oncology on 9 of the 14 factors compared between the two stocks.
Get Kura Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kura Oncology Competitors List
Related Companies and Tools
